

# Jan Adolfsson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8613587/jan-adolfsson-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18

papers

628

citations

8

h-index

22

g-index

22

ext. papers

787

ext. citations

6.5

avg, IF

3.15

L-index

#	Paper	IF	Citations
18	Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort.. <i>BJUI Compass</i> , <b>2022</b> , 3, 173-183	0.9	1
17	Guideline-based quality assurance: a conceptual framework for the definition of key elements. <i>BMC Health Services Research</i> , <b>2021</b> , 21, 173	2.9	1
16	Bringing two worlds closer together: a critical analysis of an integrated approach to guideline development and quality assurance schemes. <i>BMC Health Services Research</i> , <b>2021</b> , 21, 172	2.9	3
15	The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects. <i>European Urology Open Science</i> , <b>2021</b> , 24, 43-51	0.9	
14	Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 20-26	1.6	8
13	Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study. <i>European Urology Focus</i> , <b>2019</b> , 5, 842-848	5.1	3
12	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing. <i>European Urology Focus</i> , <b>2018</b> , 4, 707-710	5.1	30
11	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>European Urology</i> , <b>2018</b> , 74, 722-728	10.2	49
10	Predictors of participation in risk-based prostate cancer screening. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200409	3.7	6
9	The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. <i>European Journal of Cancer</i> , <b>2018</b> , 88, 101-108	7.5	3
8	Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. <i>European Urology Focus</i> , <b>2017</b> , 3, 526-528	5.1	10
7	Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1667-76	21.7	228
6	Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. <i>European Urology</i> , <b>2012</b> , 61, 690-700	10.2	12
5	Reply to Tommaso Cai, Carolina Delia, and Beatrice Detti's Letter to the Editor re: Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al. Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden. <i>Eur Urol</i> 2012;61:690-700. <i>European Urology</i> , <b>2012</b> , 61, e28	10.2	
4	Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. <i>European Urology</i> , <b>2011</b> , 60, 554-63	10.2	52
3	Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3448-56	2.2	138
2	Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 450-8	21.7	83

1 Citing and endpoints. *Scandinavian Journal of Urology*,1-1

1.6